| Document |
Document Title |
|
WO/2021/068815A1 |
Disclosed in the present invention are a carboxylic acid ester compound and an application thereof, the structure of the compound being shown in general formula I, and the definition of each substituent in general formula I being provide...
|
|
WO/2021/064189A2 |
The present invention relates to novel compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as prostaglandin E2 (PGE2) EP4 receptor antagonists, which renders them hig...
|
|
WO/2021/064142A1 |
The present invention relates to a compound of formula (I), optionally in the form of a pharmaceutically acceptable salt, solvate, cocrystal, tautomer, racemate, enantiomer, or diastereomer or mixture thereof : formula (I) and to pharmac...
|
|
WO/2021/063346A1 |
A novel KRAS G12C inhibitor. A compound represented by formula (I) and an isomer or pharmaceutically acceptable salt thereof have the following structure. The compound represented by formula (I) and a composition thereof may effectively ...
|
|
WO/2021/066319A2 |
Provided is a tertiary amine derivative which effectively absorbs a high-energy external light source in the UV region to minimize damage to organic materials in an organic electroluminescent element, thereby contributing to a substantia...
|
|
WO/2021/060723A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electronic element comprising a first electrode, a second electrode, and an organic layer placed between the first and second electrodes; and an ele...
|
|
WO/2021/019373A4 |
The present disclosure relates to nitenin analogue compounds (of formulas I, II, III and IV) and their use as pharmaceutical agent in the treatment, prevention or reduction of both acute and chronic pain. The mode of action disclosed her...
|
|
WO/2021/048229A1 |
The present invention relates to copolymers comprising moieties able to undergo a crosslinking reaction under certain stimuli, thereby forming polymer adducts having improved or additional properties, such as resistance to solvents, incr...
|
|
WO/2021/046447A1 |
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed com...
|
|
WO/2021/043755A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/037077A1 |
Patentiflorin A analogs that are useful as antivirals, such as anti-HIV, anti-coronaviral, anti-Ebola viral, and anti-influenza viral agents and methods of use thereof.
|
|
WO/2021/032687A1 |
A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, and analogues thereof, substituted in the 6-position by an arylcarbonylaminophenyl or heteroarylcarbonylaminophenyl moiety, being potent inhibitors of the growth and propa...
|
|
WO/2021/033731A1 |
Provided is a compound which is represented by formula (1). In the formula, R1-R14, L1-L3, p, q, r, n, and X1 are as defined in the specification.
|
|
WO/2021/034089A1 |
The present invention relates to a compound for an organic electronic element, an organic electronic element using same, and an electronic device including the organic electronic element. According to the present invention, an organic el...
|
|
WO/2020/254552A3 |
The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glu...
|
|
WO/2021/028362A1 |
The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).
|
|
WO/2021/023572A1 |
The present invention relates to amides of formula (I), wherein the variables are defined according to the description, process for preparation, their use as herbicides, i.e. for controlling harmful plants, and also a method for controll...
|
|
WO/2021/019373A1 |
The present disclosure relates to nitenin analogue compounds (of formulas I, II, III and IV) and their use as pharmaceutical agent in the treatment, prevention or reduction of both acute and chronic pain. The mode of action disclosed her...
|
|
WO/2021/013799A1 |
The invention relates to substituted N-phenyl uracils of the general formula (I) or salts (I) thereof, wherein the groups in the general formula (I) are as defined in the description, and to the use thereof as herbicides, more specifical...
|
|
WO/2021/008491A1 |
Biphenyl derivatives having a structure of formula (I) and capable of blocking PD-1/PD-L1 interaction, a preparation method therefor and use thereof. The series of compounds can be widely used in the preparation of medicaments for preven...
|
|
WO/2021/007659A1 |
This disclosure relates to cannabinoid derivatives having the structure of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in the treatment or prevention of a disease associated ...
|
|
WO/2021/004388A1 |
Crystal form A of a compound represented by formula (I) and an application thereof in preparing a drug for treating an SGLT1/SGLT2-related disease.
|
|
WO/2020/259471A1 |
Provided herein are oseltamivir analogs useful for the treatment and prevention of viral infections, pharmaceutical compositions comprising the same and methods preparation and use thereof.
|
|
WO/2020/260857A1 |
The present invention relates to compounds of formula I shown below: (I) wherein R1, R2 and R3 are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceuti...
|
|
WO/2020/254552A2 |
The invention relates to compounds according to general formula (I), which act as modulators of the glucocorticoid receptor and can be used in the treatment and/or prophylaxis of disorders which are at least partially mediated by the glu...
|
|
WO/2020/255021A1 |
Therapeutic combinations of hepatitis B virus (HBV) vaccines and a small molecule PDL1 or PD1 inhibitor are described. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals hav...
|
|
WO/2020/244518A1 |
The present invention provides a compound with benzyloxy aromatic ring structure represented by general formula (I), a stereoisomer, enantiomer or pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical c...
|
|
WO/2020/245665A1 |
Compounds of formula (I) wherein ring B is selected from the group consisting of Formula (B-a) and Formula (B-bc) as human cytidine triphosphate synthase 1 ( CTPS1) inhibitors for the treatment of proliferative diseases, such as e.g. can...
|
|
WO/2020/239856A1 |
Compounds of the formula (I), wherein the substituents are as defined in claim 1, useful as pesticides, and especially fungicides.
|
|
WO/2020/243754A1 |
Provided herein is a method of forming a beta-lactone from a carboxylic acid having a beta-carbon with a hydrogen atom disposed thereon. The method comprises contacting a carboxylic acid of formula (1) as described herein with an effecti...
|
|
WO/2020/233694A1 |
Disclosed are a crystal form (I) of a pyrimidine sulfonamide compound and a preparation method therefor. The present invention relates to an application thereof in the preparation of a medicament for treating diseases related to ETA rece...
|
|
WO/2020/228513A1 |
The present invention relates to the field of biomedicine, and specifically comprises a series of derivatives of a novel CDK9 inhibitor having a benzopyran structure and use thereof. In view of the disadvantages of low anti-tumor activit...
|
|
WO/2020/228789A1 |
The present invention relates to a 3-aryloxyl-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof. Specifically, the present invention provides a compound, or a pharmaceutically acceptable salt or a prodrug ...
|
|
WO/2020/223538A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
|
|
WO/2020/216701A1 |
The present invention provides acyl sulfonamide compounds of general formula (I): in which X, R1, R2, R3, R4, R5, R6, Ra and Rb are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for p...
|
|
WO/2020/218680A1 |
The present invention relates to a novel organic light emitting compound and an organic electroluminescent diode using same and, more specifically, to: a compound having excellent thermal stability, electrochemical stability, light emitt...
|
|
WO/2020/216034A1 |
Provided are an intermediate which can be used for synthesizing halichondrin B, eribulin or an analogue thereof, in particular a C27-C35 structure fragment thereof, a preparation method therefor and use thereof. The starting raw material...
|
|
WO/2020/218187A1 |
An organic electroluminescent element which comprises a light emitting layer between a positive electrode and a negative electrode facing each other, and which is characterized in that: the light emitting layer contains a first host, a s...
|
|
WO/2020/210308A1 |
The present disclosure relates to compounds of Formula (I) or (II), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
|
|
WO/2020/209035A1 |
A compound represented by formula (1). R1 is, for example, an alkyl having 1-15 carbon atoms; ring A1 and ring A2 are 1,4-phenylene, etc.; a is 2, etc.; b and c are 0, 1, or 2; Z1 is a single bond, etc.; P1 and P2 are polymerizable group...
|
|
WO/2020/205683A1 |
In immunoglobulin light chain amyloidosis (AL), the unique antibody light chain (LC) protein that is secreted by monoclonal plasma cells in each patient misfolds and/or aggregates, a process leading to organ degeneration. For treating AL...
|
|
WO/2020/189391A1 |
The present invention pertains to: a scytalone dehydratase inhibitor which contains at least one compound selected from the compounds represented by formula (I) (in the formula, A1-A4 each represents CH or N; R is a substituent other tha...
|
|
WO/2020/191091A1 |
This invention provides for compounds of the formula wherein the variables are defined herein, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, or salt thereof, compositions comprising these compounds, and method for the treatment...
|
|
WO/2020/188437A1 |
The present invention relates to compounds with a 5-(2-nitroethyI)-2,4,6- triaminopyrimidine structure, derivatised at the 1 position on the ethylene chain with heteroaromatic or phenyl-benzylether rings. The invention also relates to th...
|
|
WO/2020/188183A1 |
The invention relates to a process for producing a polybenzoxazine monomer, the crosslinking thereof, and the use of the crosslinked product to form ablative thermal protection for a propelling nozzle or a body for atmospheric re-entry.
|
|
WO/2020/188182A1 |
The invention relates to a process for producing a polybenzoxazine monomer, the crosslinking thereof and the use of the crosslinked product to form an ablative thermal protection for a thruster nozzle or an atmospheric re-entry body.
|
|
WO/2020/185420A1 |
Provided herein are integrated methods and systems for the production of acrylamide and acrylonitrile compounds and other compounds from at least beta-lactones and/or beta-hydroxy amides.
|
|
WO/2020/178404A1 |
The present invention relates to herbicidally active pyridazine derivatives of Formula (I) as defined herein, as well as to herbicidal compositions comprising such derivatives, and the use of such compounds and compositions for controlli...
|
|
WO/2020/176505A1 |
The present disclosure relates generally to certain diacylglycerol lactone compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds an...
|
|
WO/2020/175688A1 |
[Problem] To provide a fluorescent probe capable of detecting breast cancer, lung cancer, and squamous cell cancer. [Solution] A fluorescent probe for detecting breast cancer and benign tumors of the breast, the probe containing a compou...
|
